Dr Reddy's recalls its drug in the US
21 August 2015 | News | By BioSpectrum Bureau
Dr Reddy's recalls its drug in the US
It has been classified as a class-II recall
Dr Reddy's Laboratories (DRL) is recalling Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, due to 'Failed Dissolution Specifications'.
A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (US FDA). The batch was manufactured at DRL's Bachupally unit.
It has been classified as a class-II recall which FDA defined as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
